Global Retirement Partners LLC Buys 34,123 Shares of Kenvue Inc. (NYSE:KVUE)

Global Retirement Partners LLC boosted its stake in Kenvue Inc. (NYSE:KVUE) by 651.0% in the fourth quarter, HoldingsChannel reports. The firm owned 39,365 shares of the company’s stock after acquiring an additional 34,123 shares during the period. Global Retirement Partners LLC’s holdings in Kenvue were worth $840,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in KVUE. AMF Tjanstepension AB increased its holdings in Kenvue by 187.3% in the third quarter. AMF Tjanstepension AB now owns 120,477 shares of the company’s stock valued at $2,787,000 after purchasing an additional 78,540 shares during the last quarter. Sequoia Financial Advisors LLC increased its holdings in shares of Kenvue by 6.2% in the third quarter. Sequoia Financial Advisors LLC now owns 24,690 shares of the company’s stock worth $571,000 after acquiring an additional 1,449 shares in the last quarter. Signaturefd LLC increased its holdings in shares of Kenvue by 394.0% in the third quarter. Signaturefd LLC now owns 4,061 shares of the company’s stock worth $94,000 after acquiring an additional 3,239 shares in the last quarter. International Assets Investment Management LLC increased its holdings in shares of Kenvue by 1,529.5% in the third quarter. International Assets Investment Management LLC now owns 106,341 shares of the company’s stock worth $2,460,000 after acquiring an additional 99,815 shares in the last quarter. Finally, Heritage Oak Wealth Advisors LLC bought a new stake in shares of Kenvue in the third quarter worth about $375,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of NYSE KVUE opened at $23.31 on Friday. The stock has a 50 day moving average price of $21.31 and a 200 day moving average price of $22.18. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The stock has a market capitalization of $44.68 billion, a PE ratio of 43.97, a price-to-earnings-growth ratio of 2.62 and a beta of 1.45.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be given a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.52%. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on KVUE shares. Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $21.00 to $26.00 in a report on Monday, January 6th. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and lowered their price target for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. Barclays lowered their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. Citigroup lowered their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Wednesday, January 15th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, Kenvue presently has a consensus rating of “Hold” and a consensus price target of $23.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.